Response Genetics presents two gene expression analysis for personalized cancer tharapy selection
December 11, 2015
Limited gene expression profiling as predictor of response to neoadjuvant chemotherapy with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and Nab-paclitaxel and carboplatin +/- trastuzumab in patients with locally advanced Stage II-III and inflammatory breast cancer.
Pathologic complete response (pCR) following neoadjuvant chemotherapy may be a predictor of improved survival. To more effectively individualize regimens in patients with inflammatory breast cancer, researchers sought to identify molecular markers that correlate therapeutic response and/or resistance with pCR. Results show that overexpression of HER2, EGFR and BRCA2, and low expression of p27 and IGFR1 were observed in patients that achieved pCR. And when the analysis was restricted to HER2 negative cases, BRCA2 and JAK2 overexpression and low expression of IGFR1 were associated with pCR. Based on the feasibility of obtaining tissue samples before neoadjuvant chemotherapy, testing for specific genes may help determine therapeutic response in HER2+ and HER2-, locally advanced and inflammatory breast cancer.
Abstract 119: Presented Friday, December 10, 2:15 to 3:15 p.m.
Association of EGFR-activating mutations with low ERCC1 gene expression in non-small cell lung cancer: Assessment of 1,207 patients.
Published studies show that patients with NSCLC whose tumors harbor activating EGFR mutations show improved response to tyrosine kinase inhibitor-based therapy. Other studies suggest enhanced efficacy of platinum-based chemotherapy or radiotherapy in patients with EGFR mutant cancers. In this study, investigators examined the relationship between EGFR mutation status and DNA repair capacity, as exemplified by ERCC1 gene expression, as a potential explanation for this observation. Results show that NSCLC patients with EGFR activating mutations are more likely to express low ERCC1 mRNA levels. Based on these findings, a prospective trial (CASTLE) is underway to determine whether these results translate into enhanced clinical efficacy of EGFR-mutant cancers to platinum-based chemotherapy.
Source: Response Genetics Inc